Skip to contentG
Gilead Sciences, Inc.
G
GILDGilead Sciences, Inc. Source filing unavailable
Q2 2016 · —
Revenue$7.78B$7.78B−5.7% vs Q2 2015 Net Income$3.50B$3.50B−22.2% vs Q2 2015 EPS Diluted$2.58$2.58−11.6% vs Q2 2015 Gross Profit$6,787,000,000−4.8% Operating Income$4,538,000,000−19.2% Operating Cash Flowderived
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Gilead Sciences, Inc. · CIK 882095 · Engraved from SEC EDGAR
Free Cash Flowderived$4,781,000,000−12.9% Margins · derivedGross margin87.3%+0.8 pt vs Q2 2015
Operating margin58.4%−9.8 pt vs Q2 2015
Net margin45.0%−9.5 pt vs Q2 2015